Product pipeline and R&Dnegative · 3 filings
“The increase was primarily due to an upfront payment to AnaptysBio, Inc.”10-K · Feb 12, 2026 ↗
Vanda Pharmaceuticals Inc.
VNDA
Market read
Vanda Pharmaceuticals Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 18 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
Company-4.0% todayVolume comparison unavailable
Market group0 of 18 activePrecision Industrial Solutions · unavailable
Disclosed network0 of 4 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- VNDA's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if VNDA's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 18 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- VNDA's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods9
Price observations319
Usable filing statements41
Verified relationships3
Evidence supporting the case
- Latest annual revenue changed +8.7% year over year.
Evidence challenging the case
- Operating margin changed -49.5 percentage points in the latest annual period.
- Net margin changed -92.5 percentage points in the latest annual period.
- Product pipeline and R&D has repeated adverse evidence across 3 filings.
Questions before a position
- EV/sales is 94% below the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Sep 10, 2026
5.036m-43.5%12m+8.9%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2021-12-31$268.7M+8.3%$0.58+3.1%
2022-12-31$254.4M-5.3%$0.11+0.1%
2023-12-31$192.6M-24.3%$0.04+1.0%
2024-12-31$198.8M+3.2%$-0.33+1.0%
2025-12-31$216.1M+8.7%$-3.74+1.3%
What management says matters
Persistent and emerging business drivers
Valuation discipline
Descriptive valuation snapshot
Price/sales 1.4× · EV/sales 1.0×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
5.03-4.0% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for VNDA. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for VNDA. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind VNDA
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ANABAnaptysBio, Inc.partnerMay 7, 2026 ▾
“The three months ended March 31, 2025 included an upfront payment to AnaptysBio, Inc.”
TEVATeva Pharmaceutical Industries LimiteddistributorFeb 12, 2026 ▾
“For HETLIOZ ® in the treatment of Non-24, Teva and Apotex have launched their respective Abbreviated New Drug Application (ANDA) products at risk, and the FDA has also approved the ANDA for MSN.”
Depended on by
ANABAnaptysBio, Inc.partnerMay 12, 2026 ▾
“Vanda Collaboration On January 31, 2025, we entered into an Exclusive License Agreement (the “Vanda License Agreement”) with Vanda pursuant to which we granted to Vanda an exclusive, global license for the development and commercialization of imsidolimab (IL-…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 3 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
VNDA is currently a Follower in the organic co-movement group Precision Industrial Solutions. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for VNDA; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.